Checkpoint Therapeutics (NASDAQ:CKPT) Issues Quarterly Earnings Results, Misses Estimates By $0.08 EPS

Checkpoint Therapeutics (NASDAQ:CKPT) announced its quarterly earnings results on Tuesday. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.08), Zacks reports.

Checkpoint Therapeutics Trading Up 2.0 %

Shares of CKPT stock traded up $0.07 during trading hours on Wednesday, hitting $3.52. 443,164 shares of the company were exchanged, compared to its average volume of 517,390. The firm has a fifty day simple moving average of $2.73 and a 200 day simple moving average of $2.31. Checkpoint Therapeutics has a 52-week low of $1.36 and a 52-week high of $3.97.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of Checkpoint Therapeutics in a research report on Monday, September 16th.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.